Verismo Therapeutics, the U.S. subsidiary of South Korea's HLB Innovation (024850.KQ), has entered a licensing agreement with Stanford University School of Medicine for PACK-IT, a platform that generates KIR-CAR-T cells inside the body. The technology uses viral particles to deliver CAR genes directly into a patient's T-cells, potentially reducing the weeks of manufacturing and high costs associated with conventional CAR-T treatment. Verismo plans to combine PACK-IT with its proprietary KIR-CAR platform. Preclinical data presented at the American Association for Cancer Research last year showed stronger efficacy than the conventional lentivirus method and leukemia-suppressing effects. The company is conducting Phase 1 trials of KIR-CAR-based candidates for solid tumors and B-cell malignancies.